Psychosis & Schizophrenia

Psychosis & Schizophrenia - References

2. World Health Organization (WHO). Catatonic Schizophrenia. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines.1992.Geneva, Switzerland: World Health Organization.

3. Mueser KT and McGurk SR. Schizophrenia. Lancet. 2004 Jun 19;363(9426):2063-2072.

4. Nicolson R, Lenane M, Hamburger SD, Fernandez T, Bedwell J, Rapoport JL. Lessons from childhood-onset schizophrenia. Brain Research Review. 2000;31(2-3):147-156.

5. Masi G, Mucci M, Pari C. Children with schizophrenia: clinical picture and pharmacological treatment. CNS Drugs. 2006;20(10):841-866.

6. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R. Prediction of psychosis in high-risk youth: A Multi-site longitudinal study in North America. Archives of General Psychiatry. 2008 Jan;65(1):28-37.

7. Walsh E, Buchanan A, Fahy T. Violence and schizophrenia: examining the evidence. British Journal of Psychiatry. 2002 Jun;180:490-495.

8. Swanson JW, Swartz MS, Van Dorn RA, Elbogen E, Wager HR, Rosenheck RA, Stroup S, McEvoy JP, Lieberman JA. A national study of violent behavior in persons with schizophrenia. Archives of General Psychiatry. 2006 May;63(5):490-499.

9. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S, International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry. 2003 Jan;60(1):82-91.

10. Meltzer HY and Baldessarini RJ. Reducing the risk for suicide in schizophrenia and affective disorders. Journal of Clinical Psychiatry. 2003 Sep;64(9):1122-1129.

11. Blanchard JJ, Brown SA, Horan WP, Sherwood AR. Substance use disorders in schizophrenia: Reviews, integration and a proposed model. Clinical Psychological Review. 2000;20:207-234.

12. Zullino DF, Waber L, Khazaal Y. Cannabis and the course of schizophrenia. American Journal of Psychiatry. 2008;165(10):1357-1358.

13. Muller-Vahl KR and Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Review of Neurotherapeutics. 2008;8(7):1037-1048.

14. Jones RT and Benowitz NL. Therapeutics for Nicotine Addiction. In Davis KL, Charney D, Coyle JT & Nemeroff C (Eds.), Neuropsychopharmacology: The Fifth Generation of Progress (pp1533-1544). 2002. Nashville, TN:American College of Neuropsychopharmacology.

15. Cardno AG and Gottesman II. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. American Journal of Medical Genetics. 2000 Spring;97(1):12-17.

16. Harrison PJ and Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry. 2005;10(1):40-68.

17. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, Nord AS, Kusenda M, Malhotra D, Bhandari A, Stray SM, Rippey CF, Roccanova P, Makarov V, Lakshmi B, Findling RL, Sikich L, Stromberg T, Merriman B, Gogtay N, Butler P, Eckstrand K, Noory L, Gochman P, Long R, Chen Z, Davis S, Baker C, Eichler EE, Meltzer PS, Nelson SF, Singleton AB, Lee MK, Rapoport JL, King MC, Sebat J. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008 Apr 25;320(5875):539-543.

18. Huang HS, Matevossian A, Whittle C, Kim SY, Schumacher A, Baker SP, Akbarian S. Prefrontal dysfunction in schizophrenia involves missed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. Journal of Neuroscience. 2007 Oct 17;27(42):11254-11262.

19. Gogtay N and Rapoport J. Clozapine use in children and adolescents. Expert Opinion on Pharmacotherapy. 2008;9(3):459-465.

20. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine. 2005 Sep 22;353(12):1209-1223.

21. Greig TC, Zito W, Wexler BE, Fiszdon J, Bell MD. Improved cognitive function in schizophrenia after one year of cognitive training and vocational services. Schizophrenia Research. 2007 Nov;96(1-3):156-161.

22. Bell M, Fiszon J, Greig T, Wexler B, Bryson G. Neurocognitive enhancement therapy with work therapy in schizophrenia: 6-month follow-up of neuropsychological performance. Journal of Rehabilitation Research and Development. 2007;44(5):761-770.

23. Hogarty GE, Flesher S, Ulrich R, Carter M, Greenwald D, Poque-Geile M, Kechavan M, Cooley S, DiBarry AL, Garrett A, Parepally H, Zoretich R. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Archives of General Psychiatry. 2004 Sep;61(9):866-876.

Share this page

Early Intervention

Multi-Disorder Assessment

What Is A Mind Screen?

How It Works

Practice Benefits

Testimonials

Early Intervention

Multi-Disorder Assessment

What Is A Mind Screen?

How it Works

Patient Testimonials

Conditions Assessed

Early Intervention

Multi-Disorder Assessment

Mind Screen At Work

EAP+

What Others Say

Conditions Assessed

Psychosis & Schizophrenia - References

Early Intervention Find out why doing the Mind Screen early is the key to getting your patients better sooner.	Multi-Disorder Assessment Find out why the Mind Screen is superior to single-disorder assessment tools.	What Is A Mind Screen? Find out what the Mind Screen includes.
How It Works Find out how to use the Mind Screen in your daily work flow.	Practice Benefits Find out how using the Mind Screen will benefit you and your practice.	Testimonials Find out what real practitioners and patients think of the Mind Screen.

Early Intervention Find out why doing the Mind Screen is the key to getting better sooner.	Multi-Disorder Assessment Find out why you will never go back to using single-disorder assessment tools.	What Is A Mind Screen? Find out what you get when you do a Mind Screen.
How it Works Find out what to expect when doing a Mind Screen.	Patient Testimonials Find out what others say about the Mind Screen.	Conditions Assessed Find out about the 30+ conditions assessed by the Mind Screen.

Early Intervention Find out why doing the Mind Screen early is the key to getting better and back to work sooner.	Multi-Disorder Assessment Find out why the Mind Screen is simply better than single-disorder assessment tools.	Mind Screen At Work Find out how the Mind Screen will increase productivity and reduce costs at your workplace.
EAP+ Find out why the Mind Screen EAP+ Workplace Program beats traditional EAP programs hands down.	What Others Say Find out what others say about the Mind Screen.	Conditions Assessed Find out about the 30+ conditions assessed by the Mind Screen.